Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;9(1):11-3.
doi: 10.1038/nrneph.2012.262. Epub 2012 Nov 27.

Transplantation: Are calcineurin inhibitors safer than mTOR inhibitors?

Heidi Yeh  1 , James F Markmann
Affiliations
Free PMC article

Transplantation: Are calcineurin inhibitors safer than mTOR inhibitors?

Heidi Yeh et al. Nat Rev Nephrol. 2013 Jan.
Free PMC article

Abstract

Isakova et al. report that kidney transplant recipients on mammalian target of rapamycin (mTOR) inhibitors do not have a lower risk of allograft failure but do have a higher risk of death than those on calcineurin inhibitors. Careful consideration is, therefore, required before converting to mTOR inhibitors to preserve renal function.

PubMed Disclaimer

Comment on

  • Nat Rev Nephrol.

Similar articles

See all similar articles

Cited by

References

    1. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation. 2006;9:1234–1248. - PubMed
    1. Isakova T, et al. Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation. Am. J. Transplant. http://dx.doi.org/10.1111/j.1600-61432012.04281.x. - DOI - PMC - PubMed
    1. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392–395. - PMC - PubMed
    1. Bjedov I, et al. Mechanisms of life span extension by rapamycin in the fruit fly drosophila melangogaster. Cell Metab. 2010;11:35–46. - PMC - PubMed
    1. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J. Am. Soc. Nephrol. 2009;20:2493–2502. - PubMed

MeSH terms

Substances